ClinicalTrials.gg

Program

Inosine Monophosphate

Also written as “H5 Flu Investigational Medical Product (IMP) 1”, “GRT7040” and “IMP”.

Its studies are mostly in Osteoarthritis · Respiratory Syncytial Virus Infections · Acute Pain · Surgical Wound Infection, led by 4 companies.

Furthest: phase 3, since Nov 11, 20155 company-led studies, 3 open or runningNext primary completion: Apr 4, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer20 open or runningphase 3since Nov 11, 2015Nov 11, 2015none ahead
Grünenthal11 open or runningphase 2since Sep 2, 2026Sep 2, 2026Sep 2027phase 2 · NCT07807644
MB PHARMA s.r.o.11 open or runningphase 2since Mar 13, 2024Mar 13, 2024none ahead
Sanofi11 open or runningphase 1since Mar 31, 2026Mar 31, 2026Apr 4, 2027phase 1 · NCT07516418

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2015First study: phase 3 study in OsteoarthritisNew to PfizerPfizer · NCT02674386 · 154 enrolled · United States, Australia, Canada and more
  2. Jan 17, 2017Phase 3 study in OsteoarthritisPfizer · NCT03031938 · 4 enrolled · United States
  3. Mar 13, 2024MB PHARMA s.r.o.’s first study: phase 2 study in Surgical Wound InfectionNew to MB PHARMA s.r.o.MB PHARMA s.r.o. · NCT06319235 · 52 planned · Czechia
  4. Mar 31, 2026Sanofi’s first study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to SanofiSanofi · NCT07516418 · 360 enrolled · Australia
  5. Sep 2, 2026Grünenthal’s first study: phase 2 study in Acute PainNew to GrünenthalGrünenthal · NCT07807644 · 400 planned

Ahead

  1. Apr 4, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus InfectionsSanofi · NCT07516418
  2. Sep 2027Primary completion: phase 2 study in Acute PainGrünenthal · NCT07807644

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07807644Acute Pain2Not yet recruitingGrünenthalSep 2027400
NCT07516418Respiratory Syncytial Virus Infections · Australia1Active, not recruitingSanofiApr 4, 2027360
NCT06319235Surgical Wound Infection · Czechia2RecruitingMB PHARMA s.r.o.Dec 31, 202552
NCT03031938Osteoarthritis · United States3CompletedPfizerJun 4, 20204
NCT02674386Osteoarthritis · United States, Australia, Canada and more3CompletedPfizerJul 15, 2019154

How it is read

Names in the registry

  • “H5 Flu Investigational Medical Product (IMP) 1”, 1 entry
  • “GRT7040”, 1 entry
  • “IMP”, 1 entry
  • “Investigational medical product (IMP) administered in parent study”, 1 entry
  • “Investigational Medical Product (IMP) administered in parent study”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.